TY - JOUR
T1 - Human tumor antigens recognized by T lymphocytes
T2 - Implications for cancer therapy
AU - Wang, Rong Fu
AU - Rosenberg, Steven A.
PY - 1996/9
Y1 - 1996/9
N2 - The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. In the past year, a number of such tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. The majority of tumor antigens identified to date have been found to be nonmutated, self proteins. This raises important questions regarding the mechanism of antitumor activity and autoimmune disease. Several tumor-specific mutated tumor antigens have also been recently identified, which include cell cyclin-dependent kinase 4 (CDK4) and β-catenin. For the first time, a novel human cancer antigen was recently found to be generated by the use of an alternative open reading frame of the previously identified tyrosinase-related protein-1 (TRP-1) gene. The identification of human tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. The potential clinical applications of these tumor antigens will be discussed.
AB - The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. In the past year, a number of such tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. The majority of tumor antigens identified to date have been found to be nonmutated, self proteins. This raises important questions regarding the mechanism of antitumor activity and autoimmune disease. Several tumor-specific mutated tumor antigens have also been recently identified, which include cell cyclin-dependent kinase 4 (CDK4) and β-catenin. For the first time, a novel human cancer antigen was recently found to be generated by the use of an alternative open reading frame of the previously identified tyrosinase-related protein-1 (TRP-1) gene. The identification of human tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. The potential clinical applications of these tumor antigens will be discussed.
KW - β-catenin
KW - Autoimmune disease
KW - Cyclin-dependent kinase 4
KW - Interleukin-2
UR - http://www.scopus.com/inward/record.url?scp=0029814705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029814705&partnerID=8YFLogxK
U2 - 10.1002/jlb.60.3.296
DO - 10.1002/jlb.60.3.296
M3 - Review article
C2 - 8830785
AN - SCOPUS:0029814705
SN - 0741-5400
VL - 60
SP - 296
EP - 309
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
IS - 3
ER -